EP3110846 - ANTIBODIES THAT BIND EGFR AND ERBB3 [Right-click to bookmark this link] | Status | No opposition filed within time limit Status updated on 25.06.2021 Database last updated on 22.08.2024 | |
Former | The patent has been granted Status updated on 17.07.2020 | ||
Former | Grant of patent is intended Status updated on 01.04.2020 | ||
Former | Examination is in progress Status updated on 13.10.2017 | ||
Former | Request for examination was made Status updated on 02.12.2016 | Most recent event Tooltip | 27.04.2024 | Lapse of the patent in a contracting state New state(s): MK | published on 29.05.2024 [2024/22] | Applicant(s) | For all designated states Merus N.V. Yalelaan 62 3584 CM Utrecht / NL | [2017/06] |
Former [2017/01] | For all designated states Merus N.V. Padualaan 8, postvak 133 3584 CH Utrecht / NL | Inventor(s) | 01 /
LOGTENBERG, Ton c/o Yalelaan 62 3584 CM Utrecht / NL | 02 /
THROSBY, Mark c/o Yalelaan 62 3584 CM Utrecht / NL | 03 /
ROOVERS, Robertus Cornelis c/o Yalelaan 62 3584 CM Utrecht / NL | [2020/20] |
Former [2017/01] | 01 /
LOGTENBERG, Ton c/o Padualaan 8 Postvak 133 NL-3584 CH Utrecht / NL | ||
02 /
THROSBY, Mark c/o Padualaan 8 Postvak 133 NL-3584 CH Utrecht / NL | |||
03 /
ROOVERS, Robertus Cornelis c/o Padualaan 8 Postvak 133 NL-3584 CH Utrecht / NL | Representative(s) | V.O. P.O. Box 87930 Carnegieplein 5 2508 DH Den Haag / NL | [2017/01] | Application number, filing date | 15708906.1 | 27.02.2015 | [2017/01] | WO2015NL50124 | Priority number, date | EP20140157351 | 28.02.2014 Original published format: EP 14157351 | [2017/01] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2015130172 | Date: | 03.09.2015 | Language: | EN | [2015/35] | Type: | A1 Application with search report | No.: | EP3110846 | Date: | 04.01.2017 | Language: | EN | The application published by WIPO in one of the EPO official languages on 03.09.2015 takes the place of the publication of the European patent application. | [2017/01] | Type: | B1 Patent specification | No.: | EP3110846 | Date: | 19.08.2020 | Language: | EN | [2020/34] | Search report(s) | International search report - published on: | EP | 03.09.2015 | Classification | IPC: | C07K16/28, C07K16/32 | [2017/01] | CPC: |
C07K16/2863 (EP,US);
A61P35/00 (EP);
A61P35/04 (EP);
C07K16/32 (EP,US);
C07K2317/31 (EP,US);
C07K2317/565 (US);
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2017/01] | Extension states | BA | Not yet paid | ME | Not yet paid | Title | German: | EGFR- UND ERBB3-BINDENDE ANTIKÖRPER | [2017/01] | English: | ANTIBODIES THAT BIND EGFR AND ERBB3 | [2017/01] | French: | ANTICORPS QUI SE LIENT AUX EGFR ET ERBB3 | [2020/17] |
Former [2017/01] | ANTICORPS QUI SE LIENT À L'EGFR ET À L'ERBB3 | Entry into regional phase | 22.09.2016 | National basic fee paid | 22.09.2016 | Designation fee(s) paid | 22.09.2016 | Examination fee paid | Examination procedure | 22.09.2016 | Examination requested [2017/01] | 22.09.2016 | Date on which the examining division has become responsible | 06.04.2017 | Amendment by applicant (claims and/or description) | 16.10.2017 | Despatch of a communication from the examining division (Time limit: M06) | 26.04.2018 | Reply to a communication from the examining division | 30.07.2018 | Despatch of a communication from the examining division (Time limit: M06) | 08.03.2019 | Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time | 30.04.2019 | Reply to a communication from the examining division | 16.03.2020 | Cancellation of oral proceeding that was planned for 17.03.2020 | 17.03.2020 | Date of oral proceedings (cancelled) | 02.04.2020 | Communication of intention to grant the patent | 10.07.2020 | Fee for grant paid | 10.07.2020 | Fee for publishing/printing paid | 10.07.2020 | Receipt of the translation of the claim(s) | Divisional application(s) | EP20190908.2 / EP3786186 | Opposition(s) | 20.05.2021 | No opposition filed within time limit [2021/30] | Request for further processing for: | The application is deemed to be withdrawn due to failure to reply to the examination report | 30.04.2019 | Request for further processing filed | 30.04.2019 | Full payment received (date of receipt of payment) Request granted | 14.05.2019 | Decision despatched | Fees paid | Renewal fee | 31.01.2017 | Renewal fee patent year 03 | 31.01.2018 | Renewal fee patent year 04 | 22.01.2019 | Renewal fee patent year 05 | 21.01.2020 | Renewal fee patent year 06 |
Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Lapses during opposition Tooltip | HU | 27.02.2015 | AL | 19.08.2020 | AT | 19.08.2020 | CY | 19.08.2020 | CZ | 19.08.2020 | DK | 19.08.2020 | EE | 19.08.2020 | FI | 19.08.2020 | HR | 19.08.2020 | LT | 19.08.2020 | LV | 19.08.2020 | MC | 19.08.2020 | MK | 19.08.2020 | PL | 19.08.2020 | RO | 19.08.2020 | RS | 19.08.2020 | SE | 19.08.2020 | SI | 19.08.2020 | SK | 19.08.2020 | SM | 19.08.2020 | BG | 19.11.2020 | NO | 19.11.2020 | GR | 20.11.2020 | IS | 19.12.2020 | PT | 21.12.2020 | LU | 27.02.2021 | BE | 28.02.2021 | CH | 28.02.2021 | LI | 28.02.2021 | [2024/22] |
Former [2023/30] | HU | 27.02.2015 | |
AL | 19.08.2020 | ||
AT | 19.08.2020 | ||
CY | 19.08.2020 | ||
CZ | 19.08.2020 | ||
DK | 19.08.2020 | ||
EE | 19.08.2020 | ||
FI | 19.08.2020 | ||
HR | 19.08.2020 | ||
LT | 19.08.2020 | ||
LV | 19.08.2020 | ||
MC | 19.08.2020 | ||
PL | 19.08.2020 | ||
RO | 19.08.2020 | ||
RS | 19.08.2020 | ||
SE | 19.08.2020 | ||
SI | 19.08.2020 | ||
SK | 19.08.2020 | ||
SM | 19.08.2020 | ||
BG | 19.11.2020 | ||
NO | 19.11.2020 | ||
GR | 20.11.2020 | ||
IS | 19.12.2020 | ||
PT | 21.12.2020 | ||
LU | 27.02.2021 | ||
BE | 28.02.2021 | ||
CH | 28.02.2021 | ||
LI | 28.02.2021 | ||
Former [2023/27] | HU | 27.02.2015 | |
AL | 19.08.2020 | ||
AT | 19.08.2020 | ||
CZ | 19.08.2020 | ||
DK | 19.08.2020 | ||
EE | 19.08.2020 | ||
FI | 19.08.2020 | ||
HR | 19.08.2020 | ||
LT | 19.08.2020 | ||
LV | 19.08.2020 | ||
MC | 19.08.2020 | ||
PL | 19.08.2020 | ||
RO | 19.08.2020 | ||
RS | 19.08.2020 | ||
SE | 19.08.2020 | ||
SI | 19.08.2020 | ||
SK | 19.08.2020 | ||
SM | 19.08.2020 | ||
BG | 19.11.2020 | ||
NO | 19.11.2020 | ||
GR | 20.11.2020 | ||
IS | 19.12.2020 | ||
PT | 21.12.2020 | ||
LU | 27.02.2021 | ||
BE | 28.02.2021 | ||
CH | 28.02.2021 | ||
LI | 28.02.2021 | ||
Former [2022/34] | AL | 19.08.2020 | |
AT | 19.08.2020 | ||
CZ | 19.08.2020 | ||
DK | 19.08.2020 | ||
EE | 19.08.2020 | ||
FI | 19.08.2020 | ||
HR | 19.08.2020 | ||
LT | 19.08.2020 | ||
LV | 19.08.2020 | ||
MC | 19.08.2020 | ||
PL | 19.08.2020 | ||
RO | 19.08.2020 | ||
RS | 19.08.2020 | ||
SE | 19.08.2020 | ||
SI | 19.08.2020 | ||
SK | 19.08.2020 | ||
SM | 19.08.2020 | ||
BG | 19.11.2020 | ||
NO | 19.11.2020 | ||
GR | 20.11.2020 | ||
IS | 19.12.2020 | ||
PT | 21.12.2020 | ||
LU | 27.02.2021 | ||
BE | 28.02.2021 | ||
CH | 28.02.2021 | ||
LI | 28.02.2021 | ||
Former [2021/47] | AL | 19.08.2020 | |
AT | 19.08.2020 | ||
CZ | 19.08.2020 | ||
DK | 19.08.2020 | ||
EE | 19.08.2020 | ||
FI | 19.08.2020 | ||
HR | 19.08.2020 | ||
LT | 19.08.2020 | ||
LV | 19.08.2020 | ||
MC | 19.08.2020 | ||
PL | 19.08.2020 | ||
RO | 19.08.2020 | ||
RS | 19.08.2020 | ||
SE | 19.08.2020 | ||
SI | 19.08.2020 | ||
SK | 19.08.2020 | ||
SM | 19.08.2020 | ||
BG | 19.11.2020 | ||
NO | 19.11.2020 | ||
GR | 20.11.2020 | ||
IS | 19.12.2020 | ||
PT | 21.12.2020 | ||
LU | 27.02.2021 | ||
CH | 28.02.2021 | ||
LI | 28.02.2021 | ||
Former [2021/41] | AL | 19.08.2020 | |
AT | 19.08.2020 | ||
CZ | 19.08.2020 | ||
DK | 19.08.2020 | ||
EE | 19.08.2020 | ||
FI | 19.08.2020 | ||
HR | 19.08.2020 | ||
LT | 19.08.2020 | ||
LV | 19.08.2020 | ||
MC | 19.08.2020 | ||
PL | 19.08.2020 | ||
RO | 19.08.2020 | ||
RS | 19.08.2020 | ||
SE | 19.08.2020 | ||
SI | 19.08.2020 | ||
SK | 19.08.2020 | ||
SM | 19.08.2020 | ||
BG | 19.11.2020 | ||
NO | 19.11.2020 | ||
GR | 20.11.2020 | ||
IS | 19.12.2020 | ||
PT | 21.12.2020 | ||
Former [2021/36] | AL | 19.08.2020 | |
AT | 19.08.2020 | ||
CZ | 19.08.2020 | ||
DK | 19.08.2020 | ||
EE | 19.08.2020 | ||
FI | 19.08.2020 | ||
HR | 19.08.2020 | ||
LT | 19.08.2020 | ||
LV | 19.08.2020 | ||
PL | 19.08.2020 | ||
RO | 19.08.2020 | ||
RS | 19.08.2020 | ||
SE | 19.08.2020 | ||
SI | 19.08.2020 | ||
SK | 19.08.2020 | ||
SM | 19.08.2020 | ||
BG | 19.11.2020 | ||
NO | 19.11.2020 | ||
GR | 20.11.2020 | ||
IS | 19.12.2020 | ||
PT | 21.12.2020 | ||
Former [2021/28] | AL | 19.08.2020 | |
AT | 19.08.2020 | ||
CZ | 19.08.2020 | ||
DK | 19.08.2020 | ||
EE | 19.08.2020 | ||
FI | 19.08.2020 | ||
HR | 19.08.2020 | ||
LT | 19.08.2020 | ||
LV | 19.08.2020 | ||
PL | 19.08.2020 | ||
RO | 19.08.2020 | ||
RS | 19.08.2020 | ||
SE | 19.08.2020 | ||
SK | 19.08.2020 | ||
SM | 19.08.2020 | ||
BG | 19.11.2020 | ||
NO | 19.11.2020 | ||
GR | 20.11.2020 | ||
IS | 19.12.2020 | ||
PT | 21.12.2020 | ||
Former [2021/25] | AL | 19.08.2020 | |
AT | 19.08.2020 | ||
CZ | 19.08.2020 | ||
DK | 19.08.2020 | ||
EE | 19.08.2020 | ||
FI | 19.08.2020 | ||
HR | 19.08.2020 | ||
LT | 19.08.2020 | ||
LV | 19.08.2020 | ||
PL | 19.08.2020 | ||
RO | 19.08.2020 | ||
RS | 19.08.2020 | ||
SE | 19.08.2020 | ||
SM | 19.08.2020 | ||
BG | 19.11.2020 | ||
NO | 19.11.2020 | ||
GR | 20.11.2020 | ||
IS | 19.12.2020 | ||
PT | 21.12.2020 | ||
Former [2021/23] | AT | 19.08.2020 | |
CZ | 19.08.2020 | ||
DK | 19.08.2020 | ||
EE | 19.08.2020 | ||
FI | 19.08.2020 | ||
HR | 19.08.2020 | ||
LT | 19.08.2020 | ||
LV | 19.08.2020 | ||
PL | 19.08.2020 | ||
RO | 19.08.2020 | ||
RS | 19.08.2020 | ||
SE | 19.08.2020 | ||
SM | 19.08.2020 | ||
BG | 19.11.2020 | ||
NO | 19.11.2020 | ||
GR | 20.11.2020 | ||
IS | 19.12.2020 | ||
PT | 21.12.2020 | ||
Former [2021/22] | CZ | 19.08.2020 | |
DK | 19.08.2020 | ||
EE | 19.08.2020 | ||
FI | 19.08.2020 | ||
HR | 19.08.2020 | ||
LT | 19.08.2020 | ||
LV | 19.08.2020 | ||
PL | 19.08.2020 | ||
RO | 19.08.2020 | ||
RS | 19.08.2020 | ||
SE | 19.08.2020 | ||
BG | 19.11.2020 | ||
NO | 19.11.2020 | ||
GR | 20.11.2020 | ||
IS | 19.12.2020 | ||
PT | 21.12.2020 | ||
Former [2021/20] | DK | 19.08.2020 | |
FI | 19.08.2020 | ||
HR | 19.08.2020 | ||
LT | 19.08.2020 | ||
LV | 19.08.2020 | ||
PL | 19.08.2020 | ||
RS | 19.08.2020 | ||
SE | 19.08.2020 | ||
BG | 19.11.2020 | ||
NO | 19.11.2020 | ||
GR | 20.11.2020 | ||
IS | 19.12.2020 | ||
PT | 21.12.2020 | ||
Former [2021/10] | FI | 19.08.2020 | |
HR | 19.08.2020 | ||
LT | 19.08.2020 | ||
LV | 19.08.2020 | ||
PL | 19.08.2020 | ||
RS | 19.08.2020 | ||
SE | 19.08.2020 | ||
BG | 19.11.2020 | ||
NO | 19.11.2020 | ||
GR | 20.11.2020 | ||
IS | 19.12.2020 | ||
PT | 21.12.2020 | ||
Former [2021/09] | FI | 19.08.2020 | |
LT | 19.08.2020 | ||
SE | 19.08.2020 | ||
BG | 19.11.2020 | ||
NO | 19.11.2020 | ||
GR | 20.11.2020 | ||
PT | 21.12.2020 | ||
Former [2021/08] | FI | 19.08.2020 | |
LT | 19.08.2020 | ||
SE | 19.08.2020 | ||
BG | 19.11.2020 | ||
NO | 19.11.2020 | ||
PT | 21.12.2020 | ||
Former [2021/07] | FI | 19.08.2020 | |
LT | 19.08.2020 | ||
NO | 19.11.2020 | Cited in | International search | [A]US2004071696 (ADAMS GREGORY P [US], et al) [A] 1-29* claims 1-65 *; | [A]WO2008140493 (UNIV CALIFORNINA [US], et al) [A] 1-29 * paragraphs [0090] , [0096]; claims 1-66 *; | [X]WO2010108127 (GENENTECH INC [US], et al) [X] 1-29 * examples 5-19; claims 1-37 *; | [I]US2013259867 (AMLER LUKAS [US], et al) [I] 1-29 * examples 1-5 *; | [I] - SCHAEFER G ET AL, "A Two-in-One Antibody against HER3 and EGFR Has Superior Inhibitory Activity Compared with Monospecific Antibodies", CANCER CELL, CELL PRESS, US, (20111018), vol. 20, no. 4, doi:10.1016/J.CCR.2011.09.003, ISSN 1535-6108, pages 472 - 486, XP002694584 [I] 1-29 * the whole document * DOI: http://dx.doi.org/10.1016/j.ccr.2011.09.003 | by applicant | US2003078385 | WO2004009618 | WO2008027236 | WO2009157771 | US2010183615 | WO2010108127 | EP2604625 | WO2013157954 | - JUNTTILA, T. T.; K. PARSONS ET AL., "Superior In vivo Efficacy of Afucosylated Trastuzumab in the Treatment of HER2-Amplified Breast Cancer.", CANCER RESEARCH, (2010), vol. 70, no. 11, doi:doi:10.1158/0008-5472.CAN-09-3704, pages 4481 - 4489, XP002741171 DOI: http://dx.doi.org/10.1158/0008-5472.CAN-09-3704 | - SCHAEFER ET AL., CANCER CELL, (201110), vol. 20, pages 472 - 486 | - OLAYIOYE MA ET AL., EMBO J, (2000), vol. 19, pages 3159 - 3167 | - CANCER SCI., (200909), vol. 100, no. 9, pages 1566 - 72 | - J.C. ALMAGROL; J. FRANSSON, FRONTIERS IN BIOSCIENCE, (2008), vol. 13, pages 1619 - 1633 | - GUNASEKARAN, JBC, (2010), vol. 285, pages 19637 - 19646 | - SHAMES ET AL., PLOS ONE, (201302), vol. 8, no. 2, pages 1 - 10 | - YONESAKA ET AL., SCI.TRANSL.MED., (2011), vol. 3, no. 99, page 11 | - YONESAKA ET AL., SCI.TRANSL.MED., (2011), vol. 3, no. 99, page L-11 | - SCHMITZ, K.R.; K.M. FERGUSON, "Interaction of antibodies with ErbB receptor extracellular regions", EXP CELL RES, (2009), vol. 315, no. 4, doi:doi:10.1016/j.yexcr.2008.10.008, pages 659 - 70, XP025929171 DOI: http://dx.doi.org/10.1016/j.yexcr.2008.10.008 | - DE HAARD, H.J. ET AL., "A large non-immunized human Fab fragment phage library that permits rapid isolation and kinetic analysis of high affinity antibodies", J BIOL CHEM, (1999), vol. 274, no. 26, doi:doi:10.1074/jbc.274.26.18218, pages 18218 - 30, XP002128301 DOI: http://dx.doi.org/10.1074/jbc.274.26.18218 | - MARKS, J.D. ET AL., "By-passing immunization. Human antibodies from V gene libraries displayed on phage", J MOL BIOL, (1991), vol. 222, no. 3, doi:doi:10.1016/0022-2836(91)90498-U, pages 581 - 97, XP024010124 DOI: http://dx.doi.org/10.1016/0022-2836(91)90498-U | - MEULEMANS, E.V. ET AL., "Selection of phage-displayed antibodies specific for a cytoskeletal antigen by competitive elution with a monoclonal antibod", J MOL BIOL, (1994), vol. 244, no. 4, doi:doi:10.1006/jmbi.1994.1735, pages 353 - 60, XP024009278 DOI: http://dx.doi.org/10.1006/jmbi.1994.1735 | - GIARD, D.J. ET AL., "In vitro cultivation of human tumors: establishment of cell lines derived from a series of solid tumors", J NATL CANCER INST, (1973), vol. 51, no. 5, pages 1417 - 23, XP009085989 | - MERLINO, G.T. ET AL., "Amplification and enhanced expression of the epidermal growth factor receptor gene in A431 human carcinoma cells", SCIENCE, (1984), vol. 224, no. 4647, pages 417 - 9 | - COCHRAN, J.R. ET AL., "Domain-level antibody epitope mapping through yeast surface display of epidermal growth factor receptor fragments", J IMMUNOL METHODS, (2004), vol. 287, no. 1-2, doi:doi:10.1016/j.jim.2004.01.024, pages 147 - 58, XP004503477 DOI: http://dx.doi.org/10.1016/j.jim.2004.01.024 | - LEDON, N. ET AL., "Comparative analysis of binding affinities to epidermal growth factor receptor of monoclonal antibodies nimotuzumab and cetuximab using different experimental animal models", PLACENTA, (2011), vol. 32, no. 7, doi:doi:10.1016/j.placenta.2011.04.008, pages 531 - 4, XP028228236 DOI: http://dx.doi.org/10.1016/j.placenta.2011.04.008 | - GULLI, L.F. ET AL., "Epidermal growth factor-induced apoptosis in A431 cells can be reversed by reducing the tyrosine kinase activity", CELL GROWTH DIFFER, (1996), vol. 7, no. 2, pages 173 - 8 | - PASTORE S; MASCIA F; MARIOTTI F; DATTILO C; MARIANI V; GIROLOMONI G, "ERK1/2 regulates epidermal chemokine expression and skin inflammation", IMMUNOL., (2005), vol. 174, no. 8, pages 5047 - 5056, XP002410415 | - LICHTENBERGER BM; GERBER P A.; HOLCMANN M ET AL., "Epidermal EGFR Controls Cutaneous Host Defense and Prevents Inflammation", SCI TRANSL MED., (2013), vol. 5, pages 199RA111 - 199RA111 | - CHENG LIU; ANDREIA LEE, "ADCC Enhancement Technologies for Next Generation Therapeutic Antibody", ANTIBODY THERAPEUTICS -TRENDS IN BIO/PHARMACEUTICAL INDUSTRY, (2009), pages 13 - 17 | - GARRETT TP; MCKERN NM; LOU M; ELLEMAN TC; ADAMS TE; LOVRECZ GO; ZHU HJ; WALKER F; FRENKEL MJ; HOYNE PA, "Crystal structure of a truncated epidermal growth factor receptor extracellular domain bound to transforming growth factor alpha", CELL, (2002), vol. 110, doi:doi:10.1016/S0092-8674(02)00940-6, pages 763 - 73, XP002229457 DOI: http://dx.doi.org/10.1016/S0092-8674(02)00940-6 | - OGISO H; ISHITANI R; NUREKI O; FUKAI S; YAMANAKA M; KIM JH; SAITO K; SAKAMOTO A; INOUE M; SHIROUZU M, "Crystal structure of the complex of human epidermal growth factor and receptor extracellular domains", CELL, (2002), vol. 110, doi:doi:10.1016/S0092-8674(02)00963-7, pages 775 - 87, XP002961395 DOI: http://dx.doi.org/10.1016/S0092-8674(02)00963-7 | - FERGUSON KM, "Structure-based view of epidermal growth factor receptor regulation", ANNU REV BIOPHYS, (2008), vol. 37, pages 353 - 73 | - YARDEN Y, "The EGFR family and its ligands in human cancer. Signalling mechanisms and therapeutic opportunities", EUR J CANCER, (2001), vol. 37, no. 4, pages S3 - S8 | - JORISSEN RN; WALKER F; POULIOT N; GARRETT TP; WARD CW; BURGESS AW, "Epidermal growth factor receptor: mechanisms of activation and signalling", EXP CELL RES, (2003), vol. 284, pages 31 - 53 | - BUDAY L; DOWNWARD J, "Epidermal growth factor regulates p2lras through the formation of a complex of receptor, Grb2 adapter protein, and Sos nucleotide exchange factor", CELL, (1993), vol. 73, doi:doi:10.1016/0092-8674(93)90146-H, pages 611 - 20, XP027461467 DOI: http://dx.doi.org/10.1016/0092-8674(93)90146-H | - GALE NW; KAPLAN S; LOWENSTEIN EJ; SCHLESSINGER J; BAR-SAGI D, "Grb2 mediates the EGF-dependent activation of guanine nucleotide exchange on Ras", NATURE, (1993), vol. 363, pages 88 - 92 | - SOLTOFF SP; CARRAWAY KL, III; PRIGENT SA; GULLICK WG; CANTLEY LC, "ErbB3 is involved in activation of phosphatidylinositol 3-kinase by epidermal growth factor", MOL CELL BIOL, (1994), vol. 14, pages 3550 - 8 | - PRIGENT SA; GULLICK WJ, "Identification of cErbB-3 binding sites for phosphatidylinositol 30-kinase and SHC using an EGF receptor/c-ErbB-3 chimera", EMBO J, (1994), vol. 13, pages 2831 - 41, XP002467288 | - UBERALL I; KOLAR Z; TROJANEC R; BERKOVCOVA J; HAJDUCH M, "The status and role of ErbB receptors in human cancer", EXP MOL PATHOL, (2008), vol. 84, pages 79 - 89, XP022553913 | - ROBERTSON SC; TYNAN J; DONOGHUE DJ, "RTK mutations and human syndromes: when good receptors turn bad", TRENDS GENET, (2000), vol. 16, doi:doi:10.1016/S0168-9525(00)02077-1, page 368, XP004215209 DOI: http://dx.doi.org/10.1016/S0168-9525(00)02077-1 | - PATEL DK, "Clinical use of anti-epidermal growth factor receptor monoclonal antibodies in metastatic colorectal cancer", PHARMACOTHERAPY, (2008), vol. 28, pages 31S - 41S | - MERCHANT ET AL., NATURE BIOTECHNOLOGY, (199807), vol. 16, pages 677 - 681 | - NISSIM A; HOOGENBOOM HR; TOMLINSON IM; FLYNN G; MIDGLEY C; LANE D; WINTER G, "Antibody fragments from a 'single pot' phage display library as immunochemical reagents", EMBO J., (19940201), vol. 13, no. 3, pages 692 - 8 | - KUBOTA T; NIWA R; SATOH M; AKINAGA S; SHITARA K; HANAI N, "Engineered therapeutic antibodies with improved effector functions", CANCER SCI, (200909), vol. 100, no. 9, doi:doi:10.1111/j.1349-7006.2009.01222.x, pages 1566 - 72, XP055108886 DOI: http://dx.doi.org/10.1111/j.1349-7006.2009.01222.x |